C4 Therapeutics, Inc. — Director's Dealing 2021

Sep 22, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: C4 Therapeutics, Inc. (CCCC)
CIK: 0001662579
Period of Report: 2021-09-17

Reporting Person: Prokupets Elena (Director)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2021-09-17	Common Stock	S	5152	$50.0404	Disposed	48024	Indirect
2021-09-17	Common Stock	S	5688	$50.0504	Disposed	531697	Indirect
2021-09-21	Common Stock	S	4988	$50.1306	Disposed	43036	Indirect
2021-09-21	Common Stock	S	5333	$50.1425	Disposed	526364	Indirect

Footnotes

F1: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on March 12, 2021.

F2: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $50.00 to $50.18. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

F3: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on March 15, 2021.

F4: Shares held by ERP Business Holdings, L.P. The Reporting Person disclaims beneficial ownership of these shares except to the extent of her pecuniary interest therein.

F5: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $50.00 to $50.42. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.